REGN

Regeneron Pharmaceuticalsの空売り状況は、投資家がRegeneron Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Regeneron Pharmaceuticals (NASDAQ:REGN) 株価情報, 空売り情報

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

News

FDA Accepts Odronextamab BLA For Review In R/R Follicular Lymphoma, Decision Expected By July 30, 2025

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in REGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Regeneron Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $104,155, and 14 are calls, amounting to $721,715.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $460.0 to $1000.0 for Regeneron Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 49.46, with a total volume reaching 223.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $460.0 to $1000.0, throughout the last 30 days.
<h3>Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740510946_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$295.0</td>
<td>$290.0</td>
<td>$295.0</td>
<td>$460.00</td>
<td>$147.5K</td>
<td align="right">15</td>
<td align="right">0</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.8</td>
<td>$53.0</td>
<td>$53.0</td>
<td>$750.00</td>
<td>$79.5K</td>
<td align="right">127</td>
<td align="right">21</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$79.0</td>
<td>$76.0</td>
<td>$79.0</td>
<td>$950.00</td>
<td>$71.1K</td>
<td align="right">21</td>
<td align="right">9</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$143.7</td>
<td>$135.4</td>
<td>$140.51</td>
<td>$850.00</td>
<td>$70.2K</td>
<td align="right">51</td>
<td align="right">5</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$131.0</td>
<td>$123.0</td>
<td>$126.83</td>
<td>$700.00</td>
<td>$63.4K</td>
<td align="right">46</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Regeneron Pharmaceuticals</h3>
<ul>
<li>With a trading volume of 578,077, the price of REGN is up by 1.55%, reaching $724.34.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $839.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $1013. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Regeneron Pharmaceuticals, which currently sits at a price target of $759. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Regeneron Pharmaceuticals, targeting a price of $750. 
&#x2A; In a positive move, an analyst from Leerink Partners has upgraded their rating to Outperform and adjusted the price target to $834. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Regeneron Pharmaceuticals Unusual Options Activity For February 25

On Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the <a href="https://www.benzinga.com/pressreleases/25/02/g43923628/latest-db-oto-results-demonstrate-clinically-meaningful-hearing-improvements-in-nearly-all-childre" target="_blank" rel="noreferrer noopener">otoferlin (OTOF) gene</a>.
Regeneron snapped up DB-OTO through its&nbsp;$109 million acquisition&nbsp;of Decibel Therapeutics <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33664344/decibel-therapeutics-stock-soars-on-acquisition-deal-the-details" rel="noreferrer noopener">in August 2023</a>.
Congenital deafness (hearing loss present at birth) affects approximately 1.7 out of every 1,000 children born in the U.S. Approximately half of these cases have genetic causes.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43470883/regenerons-q4-earnings-surpass-estimates-launches-quarterly-dividend-and-additional-stock-buyback-program" rel="noreferrer noopener">Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program</a>
However, otoferlin-related hearing loss is ultra-rare. It is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein critical for communication between the inner ear&#8217;s sensory cells and the auditory nerve.
These include 72-week results showing speech and development progress in the first child dosed at 10 months of age and initial results in 11 children (aged 10 months to 16 years old) – three of whom received DB-OTO bilaterally (in both ears).
Among the 11 participants with at least one post-treatment assessment, 10 demonstrated a notable response, with improved hearing at various decibel hearing levels. Additionally, among five participants with 24-week assessments, three experienced improvements in average hearing thresholds to &#8220;nearly normal&#8221; or normal hearing levels.
One participant did not experience a change from their baseline hearing at 24 weeks post-dosing.
Across all 12 participants, the surgical procedure and DB-OTO were well tolerated and no adverse or serious adverse events were considered related to DB-OTO.
Five of the 12 participants experienced transient post-surgical vestibular adverse events (e.g., nystagmus, nausea, dizziness, vomiting), which resolved within 6 days of dosing.
Price Action: REGN stock closed at $713.25 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43910591/fresh-del-monte-stock-falls-as-q4-sales-earnings-miss-expectations" target="_blank" rel="noreferrer noopener">Fresh Del Monte Stock Falls As Q4 Sales &amp; Earnings Miss Expectations</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing
Speech and development progress followed dramatic improvements in hearing in first child treated in the trial
TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene. These include 72-week results showing speech and development progress in the first child dosed at 10 months of age, as well as initial results in 11 children (aged 10 months to 16 years old) – three of whom received DB-OTO bilaterally (in both ears). The latest results were presented in an oral presentation at the Association for Research in Otolaryngology's (ARO) 48th Annual MidWinter Meeting.

Regeneron Pharmaceuticals Presents Latest DB-OTO Results, Says Demonstrate Clinically Meaningful Hearing Improvements In Nearly All Children With Profound Genetic Hearing Loss In CHORD Trial; As Presented At ARO, 10 Of 11 Children With At Least One Post-Treatment Assessment Showed Notable Improvements In Hearing

In the current market session, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it actually fell by 29.69%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1740154518_0.png" alt="Past Year Chart" />

<h3>How Does Regeneron Pharmaceuticals P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Regeneron Pharmaceuticals has a lower P/E than the aggregate P/E of 98.84 of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740154518_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Regeneron Pharmaceuticals

<ul>
<li>If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025</li>
<li>Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo</li>
<li>BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions</li>
</ul>

Regeneron And Sanofi Announce FDA Priority Review For Dupixent In Bullous Pemphigoid, With Approval Decision Expected By June 2025

Regeneron Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NYSE">REGN</a>) short percent of float has risen 3.45% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 2.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Regeneron Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739801711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Regeneron Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 5.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Regeneron Pharmaceuticals's Recent Short Interest

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 12.37% on an annualized basis producing an average annual return of 24.38%. Currently, Regeneron Pharmaceuticals has a market capitalization of $74.02 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,562.19 today based on a price of $673.60 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739574009_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy. The target action date for the FDA decision is July 10, 2025.
Acceptance of the BLA resubmission follows the resolution of third-party fill/finish manufacturing issues, which was the sole approvability issue identified by the FDA in the previous submission. The BLA is supported by data from the pivotal <a href="https://www.globenewswire.com/Tracker?data=032VzgfH3Zwknll4UBWp8zhL6nLWeVfQ1uAUbAV9jnbajCy8FTsCvmUFAcFkm2eV2t8IsNs_EENj37PPYz-UlBqu0UDpGan2Fb0QI2pnGVLOoY0TTAijCF94frYMM2vmpGyaZQXMcarXAK7CoIb_u_KN_JrMo6DgxNNL8nroMNCP8WxgVYfRst4Y4E16DQxgOhjw4zyPn14Rb0E4YfjvaA==">LINKER-MM1</a> trial investigating linvoseltamab in R/R MM, and linvoseltamab is also under <a href="https://www.globenewswire.com/Tracker?data=VbdWV_4JC1drSn1toq6OXZrfe0cN2O7_-1sX29HBZEhwCraOE4NHWui62si87wvGd_evR2y4lyNT3suHRjq5Unu5_dIpapz8ZNlk4DAEdaql_zXgO3uLdRsY7W_5_Qh1i4ibQb8-BPGiH7K1yDxOsY3Mq-p-i3oU-iiMXVErUzjEtQlvuxgmzOjmgqrPDBM6FoGMQDUJhRnDgmdZPq7OZw==">review</a> by the&nbsp;European Medicines Agency (EMA) for the same patient population.
Linvoseltamab is investigational and has not been approved by any regulatory authority.

Government

Regulations

Regeneron Clears Manufacturing Hurdle as FDA Sets July 2025 Decision Date for Linvoseltamab in Multiple Myeloma

On Saturday, 4D Molecular Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population.
Additional data were provided on the durability of aflibercept expression <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43579183/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-d" rel="noreferrer noopener">for up to two years</a>.
Topline 52-Week Efficacy Results for 4D-150 3E10 vg/eye (Planned Phase 3 Dose) from Phase 2b Population Extension Cohort of PRISM (Data Cut-Off January 15, 2025):
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40945849/4d-molecular-therapeutics-stock-falls-after-follow-up-data-from-mid-stage-study-of-vision-loss-dr" rel="noreferrer noopener">4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate</a>
In a subgroup of 30 patients who received supplemental injections of Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept), an 83% reduction in injection burden was observed. This represents 0.97 mean supplemental injections per patient over 52-weeks vs. 6.0 injections projected with on-label aflibercept 2 mg Q8W.
<ul>
<li>70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks.</li>
<li>Improved and maintained best corrected visual acuity (BCVA) of +2.2 letters.</li>
<li>Durable central subfield thickness (CST) improved with fewer fluctuations, as measured by optical coherence tomography (OCT), of -11 µm; -13 µm in supplemental injection-free patients.</li>
</ul>
In the recently diagnosed subgroup, 87% required 0-1 supplemental injection, and 80% were injection-free through 52 weeks.
<ul>
<li>A 94% reduction in injection burden was observed over 52 weeks vs. 6.0 injections projected with on-label aflibercept 2 mg Q8W</li>
<li>Improved and maintained BCVA of +3.1 letters</li>
<li>Durable CST improvement with fewer fluctuations, as measured by OCT, of -10 µm; -20 µm in supplemental injection-free patients</li>
</ul>
4D-150 continues to be well tolerated during up to three years of follow-up in all patients treated with 3E10 vg/eye
No 4D-150–-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions have been observed to date
4D-150 Program Milestones
<ul>
<li>4FRONT-1 and 4FRONT-2 Phase 3 trials are expected to initiate in Q1 and Q3 2025, respectively.</li>
<li>Two-year Phase 1/2a and 18-month Phase 2b PRISM data are expected in Q4 2025.</li>
<li>Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027.</li>
</ul>
Price Action: FDMT stock is down 8.54% at $5.46 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43593007/rivian-commercial-van-now-available-for-fleets-nationwide-in-us" target="_blank" rel="noreferrer noopener">Rivian Commercial Van Now Available For Fleets Nationwide In US</a></li>
</ul>

Movers

FDMT

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Reported Saturday, Regeneron's EYLEA HD 8 mg Shares Phase 3 Results In Retinal Vein Occlusion, Significantly Reducing Injection Frequency

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 17.78% on an annualized basis producing an average annual return of 26.11%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.54 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $10,403.71 today based on a price of $714.74 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738962020_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

<ul>
<li>Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial.</li>
<li>Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1.</li>
</ul>

Contracts

IMRX

Immuneering Announced A Clinical Supply Agreement With Regeneron Pharmaceuticals For Libtayo (Cemiplimab)

Leerink Partners analyst David Risinger upgrades Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Market Perform to Outperform and raises the price target from $762 to $834.

Upgrades

Price Target

Analyst Ratings

Leerink Partners Upgrades Regeneron Pharmaceuticals to Outperform, Raises Price Target to $834

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the <a href="https://www.benzinga.com/news/econ-s">world&#8217;s two largest economies.</a>
China responded to President Donald Trump&#8216;s 10% import tariff with targeted countermeasures, including restrictions on key mineral exports to the U.S. and tariffs on American energy products.
Beijing is raising tariffs by 10%-15% on select U.S. imports, including coal, liquefied natural gas, crude oil, agricultural machinery and vehicles. Additionally, China added PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) to its &#8220;Unreliable Entity List,&#8221; citing the need to &#8220;safeguard national sovereignty, security, and development interests,&#8221; and opened an antitrust investigation on Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
Market participants had anticipated a call between Trump and Chinese President Xi Jinping on Tuesday, but media reports indicated the conversation would not happen today.
The trade developments had an immediate impact on oil markets, with West Texas Intermediate crude futures plunging 3% overnight to as low as $70 per barrel. 
Yet, prices rebounded sharply Tuesday morning following reports that Trump is considering issuing a memorandum aimed at inflicting <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43469234/trump-prepares-maximum-pressure-on-iran-oil-jumps-above-73-energy-stocks-rally">maximum economic damage on Iran</a>, potentially leading to a sharp decline in Iranian oil production.
Energy stocks outperformed on the day, while utilities lagged. 
Among individual stocks, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rocketed 22% after posting strong earnings and a revenue beat. 
In the commodities market, gold added more than 1%, extending its all-time high, and silver jumped 2.2%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) declined 2% to $99,000.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,281.54</td>
<td>1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,495.31</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,029.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,501.00</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.5% to $600.53.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% higher to $444.77.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $522.81.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.1% to $226.80.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.9%; the&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings report included: 
<ul>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): down 1.53%</li>
<li>PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.43%</li>
<li>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 10.49%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): down 11.57%</li>
<li>Archer-Daniels-Midland Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>): down 3.58%</li>
<li>KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): down 7.90%</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>): up 3.81%</li>
<li>Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>): down 0.99%</li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>): up 5.85%</li>
<li>Estee Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>): down 16.35%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): down 2.78%</li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>): up 4.00%</li>
<li>Ametek Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>): down 1.00%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 5.85%</li>
<li>Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>): up 7.62%</li>
<li>Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>): up 10.46%</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): up 4.71%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>): down 2.72%</li>
<li>Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>): down 1.51%</li>
<li>Gartner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>): up 0.77%</li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 3.41%</li>
<li>Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>): down 20.50%</li>
<li>Berry Global Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>): up 4.15%</li>
<li>WEC Energy Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>): down 1.52%</li>
<li>Hubbell Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>): down 0.55%</li>
<li>TransDigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>): down 1.60%</li>
<li>Graphic Packaging Holding Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>): down 1.76%</li>
<li>CNH Industrial NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNHI#NYSE">CNHI</a>): up 1.71%</li>
<li>Ingredion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>): down 6.12%</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>): up 7.02%</li>
<li>Ball Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>): down 8.03%</li>
<li>Lancaster Colony Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>): up 9.27%</li>
<li>Premier Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>): down 15.36%</li>
<li>MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>): up 2.92%</li>
<li>Oaktree Specialty Lending Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>): down 3.42%</li>
<li>PJT Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>): up 12.77%</li>
<li>Energizer Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>): down 4.45%</li>
<li>Silicon Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>): down 1.05%</li>
<li>Hamilton Lane Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>): down 0.01%</li>
<li>Madison Square Garden Sports Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>): down 3.74%</li>
<li>Pentair Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>): down 1.89%</li>
<li>Amcor Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>): up 3.87%</li>
<li>Inmode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>): up 2.82%</li>
<li>Willis Towers Watson Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 3.54%</li>
<li>Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>): up 7.86%</li>
<li>Mesa Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>): up 10.48%</li>
</ul>
Major companies reporting their earnings after the close are Alphabet Inc., Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Prudential Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>), Atmos Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>), Aspen Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>), Carlisle Cos. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Idex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop</a></li>
</ul>
Photo: Marek Masik via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Commodities

Global

Econ #s

Economics

Tech

$BTC

AMCR

AMGN

ARMK

ATKR

AXTA

AZPN

BALL

BERY

CNHI

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FICO

FOXA

GOOG

GOOGL

HLNE

HUBB

ILMN

INGR

INMD

JKHY

LANC

MDLZ

MLAB

MPLX

MSGS

OCSL

PINC

PLTR

PYPL

RACE

SLAB

SPOT

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?

On Tuesday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.29</a>.
The company reported sales of $3.79 billion, up 10%, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43457428/regeneron-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-initiates-quar" rel="noreferrer noopener">consensus of $3.75 billion</a>.
&#8220;Regeneron&#8217;s financial and commercial strength allows for continued investment in our industry-leading R&amp;D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity,&#8221; said Leonard S. Schleifer, Board co-Chair, President and CEO of Regeneron. 
&#8220;In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of disease states with expansive market potential.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42978906/regeneron-pipeline-aims-to-address-220-billion-therapeutic-opportunities-by-2030" rel="noreferrer noopener">Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030</a>
Fourth quarter 2024 U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;increased 2% year-over-year to $1.49&nbsp;billion, including $305 million from Eylea HD.
A lower net selling price impacted the net product sales of Eylea HD and Eylea in the fourth quarter and full year 2024 compared to the same periods of 2023. LLibtayo&#8217;s global net sales increased by 50% to $367 million.
Sanofi collaboration revenue increased in the fourth quarter and full year 2024, compared to the same periods of 2023, due to an increase in the company&#8217;s share of profits from the commercialization of antibodies, which were $1.043&nbsp;billion and $886&nbsp;million in the fourth quarter of 2024 and 2023, respectively, and $3.924&nbsp;billion and $3.137&nbsp;billion for full-year 2024 and 2023, respectively.
Dividend: Regeneron approved initiating a quarterly cash dividend program and declared a cash dividend of $0.88 per share, payable on March 20, 2025, to shareholders of record as of February 20, 2025.
The company intends to pay a cash dividend every quarter.
The company&#8217;s board of directors also authorized an additional $3.0&nbsp;billion share repurchase program, bringing the current capacity to approximately $4.5 billion.
Price Action: REGN stock is up 5.23% at $701.72 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43465388/cnh-industrial-shares-drop-after-mixed-q4-earnings-and-weaker-2025-outlook-citing-prolonged-market-headwinds" target="_blank" rel="noreferrer noopener">CNH Industrial Q4: Mixed Earnings, Weak 2025 Outlook, Prolonged Market Headwinds And More</a></li>
</ul>
Photo via Company

Earnings

Guidance

Dividends

Buybacks

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program

WIIM

Regeneron shares are trading higher after the company reported better-than-expected Q4 financial results. The company also approved a $3 billion share repurchase program and initiated a quarterly cash dividend.

Regeneron Board Authorized Additional $3B Share Repurchase Program And Initiated Quarterly Cash Dividend Of $0.88/Share

Regeneron Sees 2025 Non-GAAP Gross Margin On Net Product Sales 87%–88%

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported quarterly earnings of $12.07 per share which beat the analyst consensus estimate of $11.29 by 6.91 percent. This is a 1.77 percent increase over earnings of $11.86 per share from the same period last year. The company reported quarterly sales of $3.790 billion which beat the analyst consensus estimate of $3.751 billion by 1.04 percent. This is a 10.37 percent increase over sales of $3.434 billion the same period last year.

Earnings Beats

Regeneron Pharmaceuticals Q4 2024 Adj. EPS $12.07 Beats $11.29 Estimate, Sales $3.790B Beat $3.751B Estimate

Legal

Press Releases

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts– Hagens Berman

Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN

REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Regeneron Therapeutics, Inc. Investors of Upcoming Deadline

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN

REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit

REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

REGN DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – REGN

Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Baird

Leerink Partners

Citigroup

Piper Sandler

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Comments

Regeneron Pharmaceuticals

空売り

Regeneron Pharmaceuticals (NASDAQ:REGN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル